Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belzutifan Plus Pembro Approved for Adjuvant RCC

2.

Palliative Care Remains Uncommon in Young Adults With Cancer

3.

Nanoparticle vaccine prevents multiple cancers and stops metastasis in mice

4.

Antitumor mRNA-based vaccines show potential against gastric cancer metastasis

5.

Tumor-targeting fluorescent bacteria illuminate cancer for precision surgery


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot